We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-24.79%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.67B
AUM Growth
-$290M
(-15%)
Cap. Flow
+$300M
Cap. Flow
% of AUM
17.92%
Top 10 Holdings %
Top 10 Hldgs %
63.16%
Holding
37
New
8
Increased
12
Reduced
6
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$182M |
| 2 |
GSK
GSK
|
+$128M |
| 3 |
Ventas
VTR
|
+$124M |
| 4 |
AbbVie
ABBV
|
+$102M |
| 5 |
Universal Health Services
UHS
|
+$79.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$191M |
| 2 |
Gilead Sciences
GILD
|
+$97.5M |
| 3 |
DaVita
DVA
|
+$75M |
| 4 |
THOR
Synthorx, Inc. Common Stock
THOR
|
+$69.9M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.42% |
| 2 | Technology | 7.76% |
| 3 | Real Estate | 5.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
| $148M | 8.85% |
1,650,000
+775,000
| +89% | +$76.1M |
|
|
CHNG
2
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $130M | 7.76% |
+13,000,000
| New | +$182M |
|
3
Viatris
VTRS
$20.7B
| $116M | 6.94% |
7,795,000
-955,000
| -11% | -$18.3M |
|
|
4
GSK
GSK
$104B
| $114M | 6.79% |
+2,400,000
| New | +$128M |
|
|
5
Universal Health Services
UHS
$9.88B
| $111M | 6.66% |
1,125,000
+625,000
| +125% | +$79.1M |
|
6
Perrigo
PRGO
$1.43B
| $96.2M | 5.74% |
2,000,000
+300,000
| +18% | +$16.1M |
|
|
7
AbbVie
ABBV
$455B
| $91.4M | 5.46% |
+1,200,000
| New | +$102M |
|
8
Alkermes
ALKS
$8.39B
| $87.2M | 5.21% |
6,050,000
+1,925,000
| +47% | +$34.4M |
|
|
9
Ventas
VTR
$44.7B
| $87.1M | 5.2% |
3,250,000
+2,500,000
| +333% | +$124M |
|
10
HCA Healthcare
HCA
$85.7B
| $76.4M | 4.56% |
850,000
+450,000
| +113% | +$58.3M |
|
11
Sarepta Therapeutics
SRPT
$1.64B
| $70.9M | 4.23% |
725,000
+125,000
| +21% | +$14.3M |
|
12
Biogen
BIIB
$30.7B
| $63.3M | 3.78% |
200,000
-150,000
| -43% | -$45.5M |
|
13
Ascendis Pharma A/S
ASND
$16.5B
| $60.4M | 3.61% |
536,710
-126,290
| -19% | -$16.4M |
|
|
MNTA
14
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $54.4M | 3.25% |
2,000,000
-1,250,000
| -38% | -$34.8M |
|
15
Nektar Therapeutics
NKTR
$2.41B
| $53.5M | 3.2% |
200,000
-50,000
| -20% | -$15.5M |
|
16
Brookdale Senior Living
BKD
$3.49B
| $53M | 3.17% |
17,000,000
+4,500,000
| +36% | +$26.2M |
|
17
Tenet Healthcare
THC
$21.8B
| $50.4M | 3.01% |
3,500,000
+1,000,000
| +40% | +$28.7M |
|
18
Myriad Genetics
MYGN
$507M
| $33.6M | 2.01% |
2,350,000
+1,350,000
| +135% | +$28.5M |
|
19
Collegium Pharmaceutical
COLL
$1.17B
| $32.7M | 1.95% |
+2,000,000
| New | +$41.3M |
|
|
AMAG
20
DELISTED
AMAG Pharmaceuticals
AMAG
| $27.1M | 1.62% |
4,390,000
| – | – |
|
21
Incyte
INCY
$24.9B
| $26.4M | 1.58% |
+360,457
| New | +$27.2M |
|
|
TECX
22
Tectonic Therapeutic
TECX
$538M
| $21M | 1.25% |
112,500
+62,500
| +125% | +$14.7M |
|
|
TBIO
23
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $17.6M | 1.05% |
1,765,000
+265,000
| +18% | +$2.17M |
|
24
Puma Biotechnology
PBYI
$402M
| $16.5M | 0.98% |
+1,950,000
| New | +$18.9M |
|
25
Atara Biotherapeutics
ATRA
$73.6M
| $12.6M | 0.75% |
59,150
-58,850
| -50% | -$18.7M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Camber Capital Management held 37 positions worth $1.67B, down 15% from $1.97B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Camber Capital Management deployed $300M of net new capital in Q1 2020, opening 8 new positions and adding to 12 existing holdings. Its largest new stake was Change Healthcare Inc. Common Stock: 13,000,000 shares worth $130M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 93% a quarter earlier, followed by Technology and Real Estate.
On the sell side, the largest reduction was Biogen, an estimated $45.5M trimmed.
- Camber Capital Management's largest Q1 2020 buy was Change Healthcare Inc. Common Stock: 13,000,000 shares worth $130M.
- Camber Capital Management added most to Ventas in Q1 2020, an estimated $124M increase.
- Camber Capital Management's biggest Q1 2020 reduction was Biogen, cutting an estimated $45.5M.
- Camber Capital Management fully exited Allergan plc in Q1 2020, selling an estimated $191M.
- Camber Capital Management's ten largest holdings make up 63% of its $1.67B portfolio in Q1 2020.
- Camber Capital Management opened 8 new positions and closed 8 in Q1 2020.
- Camber Capital Management's portfolio value fell 15% quarter-over-quarter to $1.67B.
Based on Camber Capital Management's 13F filing for Q1 2020, filed 15 May 2020.